Table 2. Unadjusted symptomatic secondary attack rates and odds ratios for secondary SARS-CoV-2 infection (probable and confirmed secondary cases), United Kingdom, January to March 2020 (n =440).
Variable levels | SAR | 95% CI | OR | 95% CI | |
---|---|---|---|---|---|
Household | |||||
Household size | 2 | 0.49 | 0.37–0.60 | 1.00 | Reference value |
3 | 0.41 | 0.30–0.51 | 0.62 | 0.26–1.53 | |
4 | 0.32 | 0.22–0.42 | 0.36 | 0.15–0.90 | |
≥ 5 | 0.25 | 0.13–0.37 | 0.23 | 0.07–0.71 | |
Interactions | |||||
Sex | Male → Male | 0.37 | 0.26–0.48 | 1.00 | Reference value |
Male → Female | 0.42 | 0.33–0.50 | 1.36 | 0.69–2.69 | |
Female → Male | 0.34 | 0.26–0.43 | 0.85 | 0.34–2.13 | |
Female → Female | 0.29 | 0.16–0.42 | 0.59 | 0.19–1.84 | |
Comorbidities | None → none | 0.37 | 0.29–0.45 | 1.00 | |
None → comorbidities | 0.46 | 0.30–0.62 | 1.70 | 0.58–4.95 | |
Comorbidities → none | 0.36 | 0.25–0.47 | 0.95 | 0.39–2.29 | |
Comorbidities → comorbidities | 0.46 | 0.28–0.64 | 1.71 | 0.53–5.56 | |
Characteristics of contact | |||||
Sex | Male | 0.36 | 0.29–0.43 | 1.00 | Reference value |
Female | 0.38 | 0.31–0.45 | 1.15 | 0.68–1.94 | |
Age group (years) | < 18 | 0.30 | 0.21–0.39 | 0.62 | 0.28–1.38 |
18–34 | 0.37 | 0.28–0.47 | 1.00 | Reference value | |
35–64 | 0.43 | 0.35–0.51 | 1.38 | 0.67–2.85 | |
≥ 65 | 0.35 | 0.13–0.57 | 0.86 | 0.19–3.87 | |
Characteristics of primary case | |||||
Sex | Male | 0.41 | 0.33–0.49 | 1.00 | Reference value |
Female | 0.33 | 0.25–0.41 | 0.61 | 0.30–1.26 | |
Age group (years) | < 18 | 0.89 | 0.7–1.05 | 41.89 | 4.46–393.02 |
18–64 | 0.35 | 0.29–0.41 | 1.00 | ||
≥ 65 | 0.42 | 0.25–0.59 | 1.51 | 0.53–4.26 | |
Hospital admission | Without hospital admission | 0.43 | 0.36–0.51 | 1.00 | Reference value |
With hospital admission | 0.28 | 0.20–0.36 | 0.37 | 0.18–0.77 | |
Cough sneezing | Without cough/sneeze | 0.32 | 0.19–0.46 | 1.00 | |
With cough/sneeze | 0.38 | 0.32–0.44 | 1.42 | 0.54–3.70 | |
Overall | 0.37 | 0.31–0.43 | NA |
CI: confidence interval; NA: not applicable; OR: odds ratio; SAR: secondary attack rate; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.